Abstract
Fenofibrate (FF) and ezetimbe (EZ) treatments of dyslipidemia prevent cardiovascular diseases by decreasing serum cholesterol (TC) and triacylglycerols (TAG) levels. Despite of FF, a PPAR-a agonist, increases lipids oxidation and EZ inhibits intestinal cholesterol uptake, it is not clear whether lipids absorption reduce after FF and EZ administration, which would directly impact the lipem…